WO2022014703A1 - 筋疾患の予防または治療剤 - Google Patents

筋疾患の予防または治療剤 Download PDF

Info

Publication number
WO2022014703A1
WO2022014703A1 PCT/JP2021/026798 JP2021026798W WO2022014703A1 WO 2022014703 A1 WO2022014703 A1 WO 2022014703A1 JP 2021026798 W JP2021026798 W JP 2021026798W WO 2022014703 A1 WO2022014703 A1 WO 2022014703A1
Authority
WO
WIPO (PCT)
Prior art keywords
mrln
muscle
muscular dystrophy
inhibitor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/026798
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
潔 石川
俊平 村田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to JP2022536461A priority Critical patent/JPWO2022014703A1/ja
Priority to US18/005,520 priority patent/US20230272386A1/en
Priority to EP21842938.9A priority patent/EP4183416A4/en
Priority to CN202180061076.3A priority patent/CN116209478A/zh
Publication of WO2022014703A1 publication Critical patent/WO2022014703A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Definitions

  • the present invention relates to a drug for preventing or treating a muscle disease.
  • the dystrophin-glycoprotein complex plays a role in connecting skeletal muscle and extracellular matrix.
  • DGC is composed of proteins such as dystrophin, sarcoglycan, and dystroglycan.
  • proteins such as dystrophin, sarcoglycan, and dystroglycan.
  • DMD Duchenne muscular dystrophy
  • DMD is the most frequently occurring muscular dystrophy, affecting boys with an estimated frequency of 1 in 3,000.
  • DMD is one of the most severe types of muscular dystrophy, and around the age of 10, he becomes unable to walk and becomes wheelchair-bound.
  • BMD Becker muscular dystrophy
  • LGMD limb-girdle muscular dystrophy
  • Sarcoglycanopathies are also a severe form, many of which exhibit clinical symptoms similar to DMD.
  • Non-Patent Document 1 Muscular dystrophy caused by deficiency of proteins constituting DGC is considered to be one of the causes of pathological progression due to abnormal intracellular calcium regulation. It has been reported that DMD improves the pathological condition of muscular dystrophy when the expression of Sarcoplasmic / Endoplasmic Reticulum Calcium ATPase (SERCA) 1 is enhanced in the skeletal muscle of the model mouse (Non-Patent Document 2). Similarly, in a mouse model of sarcoglycanopathy, it has been clarified that the pathological condition of muscular dystrophy is improved by increasing the expression of SERCA1 (Non-Patent Document 3).
  • SERCA Sarcoplasmic / Endoplasmic Reticulum Calcium ATPase
  • SERCA is a protein that is localized in the endoplasmic reticulum membrane and plays a role of a pump that takes calcium from the cytoplasm into the endoplasmic reticulum, thereby contributing to the regulation of the intracellular calcium amount.
  • SERCA1 is specifically expressed in skeletal muscle. The type.
  • MLLN Myoregluin
  • Non-Patent Document 5 As described above, although the relationship between MRLN and SERCA1 has been reported, the relationship between the suppression of MRLN expression and the pathophysiology of muscular diseases such as muscular dystrophy has not been reported.
  • An object of the present invention is to provide a drug for treating or preventing a muscle disease such as muscular dystrophy.
  • an MRLN inhibitor is effective for the treatment and prevention of muscle diseases, and have completed the present invention.
  • the gist of the present invention is as follows. [1] A prophylactic or therapeutic agent for muscle diseases containing a Myoregluin inhibitor as an active ingredient. [2] The prophylactic or therapeutic agent according to [1], wherein the Myoregluin inhibitor is a nucleic acid. [3] The prophylactic or therapeutic agent according to [2], wherein the Myoregulin inhibitor is an antisense oligonucleotide against Myoregulin. [4] The prevention according to any one of [1] to [3], wherein the muscle disease is selected from the group including muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy and sarcopenia. Or a remedy.
  • the prophylactic or therapeutic agent according to [4], wherein the muscular dystrophy is selected from the group containing Duchenne muscular dystrophy, Becker muscular dystrophy, and sarcoglycanopathies.
  • the prophylactic or therapeutic agent according to [4], wherein the muscular dystrophy is Duchenne muscular dystrophy.
  • the present invention it is possible to improve the symptoms of muscular diseases such as muscular dystrophy, and a drug effective for the prevention and treatment of the diseases is provided.
  • the graph which shows the MRLN expression inhibitory effect by MRLN-specific antisense oligonucleotide The graph which shows the expression level ratio of MRLN and the value of creatine kinase (CK) when MRLN-specific antisense oligonucleotide was administered to mdx mouse. The graph which shows the expression level ratio of MRLN and the value of CK when MRLN-specific antisense oligonucleotide was administered to Sgcb knockout mouse. The graph which shows the result of having compared the 4-Chloromethcationone (CMC) -dependent increase in calcium concentration with the addition of MRLN-specific siRNA in the cell derived from a DMD patient with the addition of a negative control.
  • CMC 4-Chloromethcationone
  • MLLN means an oligonucleotide or protein called Myoregluin.
  • MLLN includes, for example, various splicing variants transcribed from the MRLN gene, sequence variants such as single nucleotide polymorphisms (SNPs), and variant proteins translated from them.
  • SNPs single nucleotide polymorphisms
  • Nucleobase means a heterocyclic moiety that can be paired with the base of another nucleic acid.
  • Nucleobase sequence means a continuous sequence of nucleobases constituting an oligonucleotide.
  • Nucleoside means a molecule in which a sugar and a nucleobase are linked. In certain embodiments, the nucleoside is linked to a phosphate group.
  • Nucleotide means a molecule in which a phosphate group is bonded to the sugar portion of a nucleoside.
  • the naturally occurring nucleotide has a sugar moiety of ribose or deoxyribose, which is covalently bonded by a phosphodiester bond via a phosphate group.
  • Oligonucleotide means a polymer of nucleosides in which each nucleoside and the bonds between each nucleoside are linked independently of each other.
  • “Complementary” means the ability of the first nucleic acid to form a pair between the nucleobases of the second nucleic acid.
  • adenine is complementary to thymidine or uracil.
  • cytosine is complementary to guanine.
  • 5-methylcytosine is complementary to guanine.
  • “Completely complementary (also referred to as complementary)” or “100% complementary (also referred to as complementary)” means that all of the nucleobases in the nucleic acid base sequence of the first nucleic acid are the second of the second nucleic acid. Means having a complementary nucleobase in the nucleobase sequence of.
  • the first nucleic acid is a modified oligonucleotide and the target nucleic acid is a second nucleic acid.
  • Modified nucleoside means a nucleoside having a modified sugar and / or a modified nucleobase.
  • Modified oligonucleotide means an oligonucleotide containing at least one of the modified nucleosides and / or the linkage between the modified nucleosides.
  • Nucleoside bond refers to a chemical bond between nucleosides
  • modified nucleoside bond is a substitution from a naturally occurring nucleoside bond (ie, a 3'-5'phosphodiester nucleoside bond) or any of them. Refers to change. For example, there are, but are not limited to, phosphorothioate nucleoside linkages.
  • Phosphodiester bond between nucleosides means a bond between nucleosides in which the phosphodiester bond is modified by replacing one of the non-crosslinked oxygen atoms with a sulfur atom.
  • Modified base refers to any nucleobase other than adenine, cytosine, guanine, thymidine or uracil. For example, there is, but is not limited to, 5-methylcytosine.
  • Unmodified nucleobase means the purine bases adenine (A) and guanine (G), as well as the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • “Sugar” or “sugar moiety” means a natural sugar moiety or a modified sugar moiety.
  • Modified sugar refers to a substitution or modification from a naturally occurring sugar, such as a substituted sugar moiety and a bicyclic sugar.
  • the "substituted sugar moiety” means a furanosyl other than the natural sugar of RNA or DNA
  • the "bicyclic sugar” is a furanosyl ring modified by cross-linking two different carbon atoms existing on the same ring.
  • “Bicyclic nucleic acid” refers to a nucleoside or nucleotide in which the furanose portion of the nucleoside or nucleotide comprises a "bicyclic sugar”.
  • RNA is an abbreviation for small interfering RNA, and is a double-stranded RNA consisting of about 20 to 30 base pairs used for gene silencing by RNA interference (RNAi). Also, shRNA is an abbreviation for short hairpin RNA, which is a hairpin-type RNA sequence used for gene silencing by RNA interference.
  • an “antibody” is a polypeptide that specifically binds to a specific antigen, and includes polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments.
  • Compound means all substances generated by chemical bonds of atoms such as C, H, O, N, S, and includes low molecular weight compounds, peptides, sugars, high molecular weight compounds and the like.
  • administering means giving the drug to an animal, and includes, but is not limited to, administration by a medical expert and self-administration.
  • Effective amount means the amount of the modified oligonucleotide of the invention that is sufficient to achieve the desired physiological outcome in an individual in need of the drug. Effective amounts vary among individuals depending on the health and physical condition of the individual being treated, the taxon of the individual being treated, the formulation of the composition, the assessment of the individual's medical condition and other relevant factors. obtain.
  • Prevention delays or delays the onset or onset of a disease, disorder or unfavorable health condition, or one or more symptoms associated with the disease, disorder or unfavorable health condition, over a period of minutes to indefinitely. It means to prevent it. Prevention also means reducing the risk of developing a disease, disorder or unfavorable health condition.
  • Treatment alleviates, improves, delays, or eliminates a disease, disorder or unfavorable health condition, or one or more symptoms associated with the disease, disorder or unfavorable health condition. Or means to partially eliminate or eradicate one or more causes of the disease, disorder, or unfavorable health condition itself.
  • Certain specific embodiments shown below are not limited to these, but the present invention is a prophylactic or therapeutic agent for muscle diseases (hereinafter referred to as an agent of the present invention) containing a Myoregluin inhibitor as an active ingredient. May) provide.
  • an agent of the present invention a prophylactic or therapeutic agent for muscle diseases
  • Myoregluin inhibitor a Myoregluin inhibitor as an active ingredient. May
  • Myoregulin> Myoregluin is a micropeptide that is expressed in skeletal muscle and regulates the amount of calcium in muscle vesicles, specifically, suppresses the uptake of calcium in muscle vesicles.
  • the MLLN may be any MLLN expressed in mammals such as humans and mice, but human MRLN is preferable.
  • Examples of the nucleic acid base sequence of the mouse MRLN gene include a nucleic acid base sequence (SEQ ID NO: 1) registered in NCBI GenBank under accession number NM_001304739.1, and an amino acid of the mouse MRLN protein encoded by the nucleic acid base sequence. The sequence includes SEQ ID NO: 2.
  • nucleic acid base sequence of the human MRLN gene examples include a nucleic acid base sequence (SEQ ID NO: 3) registered in NCBI GenBank under accession number NM_001304731, and the amino acid of the human MRLN protein encoded by the nucleic acid base sequence.
  • the sequence includes SEQ ID NO: 4.
  • T shall be read as U in SEQ ID NOs: 1 and 3.
  • the sequence of the MRLN gene may differ depending on the individual, the sequence is not limited to the above sequence, and it regulates calcium in muscle vesicles, specifically, calcium in muscle vesicles.
  • the nucleobase sequence of mouse MRLN may be a nucleobase sequence having 90%, 95%, or 98% or more identity with SEQ ID NO: 1.
  • the nucleobase sequence of the human MRLN gene may be a nucleobase sequence having 90%, 95%, or 98% or more identity with SEQ ID NO: 3.
  • amino acid sequences of the mouse MRLN protein are 90% and 95% of SEQ ID NO: 2 as long as they have a function of regulating calcium in the muscle vesicle, specifically, suppressing the uptake of calcium in the muscle vesicle.
  • amino acid sequence of the human MRLN protein is an amino acid sequence having 90%, 95%, or 98% or more identity with SEQ ID NO: 4. May be good.
  • MLLN inhibitors include substances that inhibit the function of MRLN and substances that inhibit its expression.
  • the function of MRLN includes, for example, the function of suppressing calcium uptake into the sarcoplasmic reticulum.
  • MRLN inhibitors are substances that can increase calcium uptake into the sarcoplasmic reticulum.
  • the effect of increasing the uptake of calcium by the MRLN inhibitor into the sarcoplasmic reticulum may be due to the release of the suppression of SERCA1 activity.
  • the increase in calcium uptake into the sarcoplasmic reticulum can be measured by the system described below, and the agent of the present invention measures calcium uptake into the sarcoplasmic reticulum when the agent is not added or when a negative control is added. It is preferable to increase it 1.1 times or more, preferably 1.2 times or more, and more preferably 1.5 times or more.
  • the agent of the present invention may be an agent that directly acts on MRLN to inhibit the above function, or may be an agent that indirectly acts on MRLN and inhibits the above function.
  • inhibition of MRLN expression means reducing the amount of any one or more of MRLN pre-mRNA, mRNA and protein.
  • Inhibition of MRLN expression can be evaluated by the expression measurement system described later, and the agent of the present invention measures the amount of pre-mRNA, mRNA and / or protein of MRLN when the agent is not added or when a negative control is added. It is preferable to reduce it to 70% or less, preferably to 50% or less, and preferably to 30% or less.
  • MLLN inhibitor is not particularly limited as long as it is a substance capable of inhibiting the function and / or expression of MLLN, and examples thereof include nucleic acids (oligonucleotides), antibodies, and compounds.
  • nucleic acid as an MRLN inhibitor examples include antisense oligonucleotides against MRLN, siRNA, shRNA, and vectors expressing these, and antisense oligonucleotides against MRLN are preferably used.
  • the antisense oligonucleotide against MLLN consists of 10 to 50 bases, preferably 15 to 30 bases, and has a nucleic acid base sequence of MRLN (for example, SEQ ID NOs: 1, 3 or 90%, 95%, or 98% or more thereof).
  • An antisense oligonucleotide containing at least 8 consecutive nucleobase sequences (hereinafter referred to as "MRLN complementary nucleobase sequences") that are 100% complementary to the equal length portion of the nucleobase sequence having the same identity. Is preferable.
  • the equal-length portion as used herein means a portion having complementarity between the nucleic acid base sequence of the antisense oligonucleotide and the nucleic acid base sequence of MRLN.
  • the antisense oligonucleotide for MRLN may be any one having a nucleobase sequence having a total length of 10 to 50 bases including the above-mentioned MRLN complementary nucleobase sequence, and may be one or more in a portion other than the MRLN complementary nucleobase sequence. It may have a mismatched nucleobase or an additional base, and has an overall length of 85% or more, 90% or more, preferably 95% with respect to the equilong portion of the nucleobase sequence of MRLN (for example, SEQ ID NOs: 1 and 3). It may have the above-mentioned complementarity.
  • the complementarity percent of the nucleic acid base sequence of MRLN and the antisense oligonucleotide which is an MRLN inhibitor is, for example, a BLAST program (basic local coincidental sequence software) known in the art, a PowerBLAST program (Altschul et al., J.). .Mol.Biol., 1990,215,403410; Zhang and Madden, GenomeRes., 1997,7,649,656), it can be determined by convention using the default settings of the Geneticx software (GENETYX CORPORATION). can.
  • Percent of homology, sequence identity or complementarity can be determined, for example, by the Gap Program (WisconsinSequence Analysis Package, Version 8 for Unix, Genetics Computer Group, Universals Computer Group, University ResearchAp.M. It can be determined using the default settings using the algorithms of., 1981, 2, 482, 489) and the default settings of the Genetyx software (GENETYX CORPORATION).
  • Gap Program WidesinSequence Analysis Package, Version 8 for Unix, Genetics Computer Group, Universals Computer Group, University ResearchAp.M. It can be determined using the default settings using the algorithms of., 1981, 2, 482, 489) and the default settings of the Genetyx software (GENETYX CORPORATION).
  • the antisense oligonucleotide against MRLN can be a modified oligonucleotide.
  • the modified oligonucleotide may contain a modified base such as 5-methylcytosine, or may contain a modified sugar in at least one nucleoside constituting the oligonucleotide. Further, the nucleoside bond may be modified.
  • the modified sugar means a modified sugar moiety
  • a modified oligonucleotide containing one or more of the modified sugars has advantageous features such as enhanced nuclease stability and increased binding affinity.
  • At least one of the modified sugars preferably has a bicyclic sugar or a substituted sugar moiety.
  • nucleosides with modified sugars are 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'-F, 2'-OCH 3 , 2'-OCH 2 CH 3 , 2 Included are nucleosides containing the'-OCH 2 CH 2 F and 2'-O (CH 2 ) 2 OCH 3 substituents. Substituents at the 2'position are allyl, amino, azide, thio, O-allyl , OC 1 to C 10 alkyl, OCF 3 , OCH 2 F, O (CH 2 ) 2 SCH 3 , O (CH 2 ).
  • each R l , R m and R n are independently H or substituted or unsubstituted C 1 to C 10 alkyl). You can also choose from.
  • nucleosides with bicyclic sugars examples include nucleosides containing crosslinks between the 4'and 2'ribosyl ring atoms.
  • the oligonucleotides provided herein comprise a nucleoside having one or more bicyclic sugars whose cross-linking comprises one of the following formulas: 4'-(CH 2). ) -O-2'(LNA);4'-(CH 2 ) -S-2';4'-(CH 2 ) 2- O-2'(ENA);4'-CH (CH 3 ) -O -2'and 4'-CH (CH 2 OCH 3 ) -O-2' (and their analogs, see US Pat. No.
  • the nucleoside containing a bicyclic sugar can be a nucleoside containing a sugar moiety of the crosslinked artificial nucleic acid ALNA disclosed in WO2020 / 100926, for example, represented by the following general formula (I). It can be a nucleoside containing a sugar moiety of ALNA [Ms].
  • B is a nucleobase
  • R 1 , R 2 , R 3 and R 4 are C 1-6 alkyl groups, each independently of which may be substituted with a hydrogen atom or one or more substituents
  • R 5 and R 6 are each independently a hydrogen atom, a protecting group for a hydroxyl group, a phosphate group which may be substituted, a covalent bond to a phosphorus moiety or a support, and the like
  • m is 1 or 2
  • M is a sulfonyl group substituted with a methyl group optionally substituted with one or more substituents.
  • a typical embodiment of ALNA [Ms] is a nucleoside, which is a sulfonyl group in which M is substituted with an unsubstituted methyl group.
  • the antisense oligonucleotide as an MRLN inhibitor has a nucleobase sequence in which at least one nucleobase is cytosine.
  • the at least one cytosine is the modified nucleobase 5-methylcytosine.
  • RNA and DNA The naturally occurring nucleoside bond between RNA and DNA is a 3'-5'phosphodiester bond.
  • modified, i.e., non-naturally occurring, oligonucleotides with nucleoside linkages include, for example, enhanced cell uptake, enhanced affinity for target nucleic acids and increased stability in the presence of nucleases. Often preferred over naturally occurring oligonucleotides with internucleoside linkages because of their properties. Oligonucleotides with modified nucleoside bonds include nucleoside bonds that retain a phosphorus atom and nucleoside bonds that do not have a phosphorus atom.
  • Representative phosphorus-containing nucleoside bonds include, but are not limited to, one or more of phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidates and phosphorothioates. Methods for preparing phosphorus-containing and non-phosphorus-containing bonds are well known.
  • the internucleoside linkages of the antisense oligonucleotide as the MRLN inhibitor are all phosphorothioate nucleoside linkages.
  • the antisense oligonucleotide as an MRLN inhibitor can be synthesized by a conventional method, and can be easily synthesized by, for example, a commercially available nucleic acid synthesizer.
  • the nucleoside sugar-modified ALNA [Ms] which may be included in the antisense oligonucleotide, can be synthesized by the method disclosed in WO2020 / 100826.
  • SiRNA for MRLN has a sequence complementary to a partial sequence of MRLN mRNA (usually 20 bases or more, preferably 21 bases or more, and usually 30 bases or less, preferably 27 bases or less, more preferably 23 bases or less). It is not particularly limited as long as it is a double-stranded oligo RNA and can inhibit the expression of MRLN by specifically recognizing and cleaving the transcript. Those skilled in the art have been used to inhibit the expression of human or mouse MRLN based on the nucleic acid base sequence of the mouse MRLN gene set forth in SEQ ID NO: 1 or the nucleic acid base sequence of the human MRLN gene set forth in SEQ ID NO: 3.
  • the sequence of the sense strand and antisense strand of the resulting siRNA can be determined.
  • the synthesis of siRNA may be carried out by a method known per se, for example, the sense strand and the antisense strand can be synthesized by DNA / RNA chemical synthesis or enzymatic synthesis, respectively, and annealed thereof.
  • any virus used in the art can be used, for example, a plasmid derived from Escherichia coli (eg, pBR322, pBR325, pUC12, pUC13), a plasmid derived from bacteriophage (eg, pUB110, etc.).
  • pTP5, pC194), yeast-derived plasmids (eg, pSH19, pSH15), bacteriophage such as ⁇ phage, animal viruses such as retrovirus, vaccinia virus, baculovirus, etc., as well as pA1-11, pXT1, pRc / CMV, pRc. / RSV, cDNAI / Neo and the like can be mentioned.
  • the antibody against MRLN it is preferable to use an antibody that specifically binds to MRLN and an antagonist antibody that inhibits the function of MRLN by binding.
  • antibody refers to natural antibodies such as polyclonal antibodies and monoclonal antibodies, chimeric antibodies that can be produced using gene recombination technology, humanized antibodies and single-stranded antibodies, and human antibody-producing transgenic animals. And the like, human antibodies that can be produced using, etc., antibodies produced by phage display and binding fragments thereof are included.
  • the binding fragment means a region of a part of the antibody described above, and specifically, for example, F (ab') 2, Fab', Fab, Fv (variable fragment of antibody), sFv, dsFv (disulphide studied Fv). , DAb (single domain antibody) and the like (Exp. Opin. Ther. Patents, Vol. 6, No. 5, P. 441-456, 1996).
  • the class of antibody is not particularly limited, and includes antibodies having any isotype such as IgG, IgM, IgA, IgD or IgE. It is preferably IgG or IgM, and more preferably IgG in consideration of easiness of purification and the like.
  • the polyclonal antibody can be produced, for example, as follows. That is, immunosensitization is achieved by injecting the immunogen subcutaneously, intramuscularly, intravenously, into the hood pad or intraperitoneally in animals such as mice, rats, hamsters, guinea pigs, goats, horses or rabbits. Give. Usually, immunization is performed 1 to 5 times every 1 to 14 days after the initial immunization, and serum is obtained from the immunosensitized mammal about 1 to 5 days after the final immunization.
  • the serum As it is as a polyclonal antibody, it is preferable to use ultrafiltration, sulfur fractionation, euglobulin precipitation method, caproic acid method, capricyl acid method, ion exchange chromatography (DEAE or DE52, etc.), anti-antibody. Isolation and / or purification by affinity column chromatography using an immunoglobulin column or protein A / G column, a column cross-linked with an immunogen, or the like.
  • the monoclonal antibody can be produced, for example, as follows. That is, a hybridoma was prepared from antibody-producing cells obtained from immunosensitizers such as mice, rats or hamsters to which immunogen was administered, and myeloma cells (myeloma cells) incapable of producing autoantibodies, and the hybridoma was prepared. It is produced by selecting a clone that produces a monoclonal antibody that is cloned and exhibits a specific affinity for the immunogen used for mammalian immunization.
  • hybridomas that secrete monoclonal antibodies
  • myeloma cells used for cell fusion include mouse-derived myeloma p3 / X63-AG8.653 (653; ATCC No. CRL1580), p3 / NSI / 1-Ag4-1 (NS-1), p3 / X63-Ag8. ..
  • U1 (p3U1), SP2 / 0-Ag14 (Sp2 / 0, Sp2), PAI, F0 or BW5147, rat-derived myeloma 210RCY3-Ag. 2.3.
  • Human-derived Mieroma U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11 or CEM-T15 can be used.
  • the reactivity of the hybridoma to the immunogen used in the aforementioned immunosensitization eg, the culture supernatant of the wells in which proliferation was observed, was cultured in a microtiter plate. It can be carried out by measuring by an enzyme immunoassay method such as ELISA.
  • the monoclonal antibody is preferably isolated and / or purified in the same manner as the polyclonal antibody described above.
  • the chimeric antibody is, for example, "Experimental Medicine (Temporary Special Issue), Vol. 6, No. 10, 1988", Japanese Patent Publication No. 3-73280
  • the humanized antibody is, for example, Japanese Patent Publication No. 4-506458.
  • human antibodies for example, "Nature Genetics, Vol. 15, P.146-156, 1997", “Nature Genetics, Vol. 7, P.13-21, 1994", JP-A-62-296890, etc.
  • antibodies such as Fab can be easily obtained by collecting and concentrating phages having an affinity for an antigen from a phage library prepared for antibody screening, for example, by biopanning. can.
  • phage display "Nature, Vol. 348, P.552-554, 1990”, “” Page display a laboratory manual “In Cold Spring Harbor Laboratory Press, 2001”, “Antibody”, “Antibody”. IRL Press, Oxford, 1996 ".
  • F (ab) 2 and Fab' can be produced by treating the immunoglobulin with the proteolytic enzyme pepsin or papain, respectively.
  • Fab can be produced by screening the Fab-expressing phage library in the same manner as in the antibody production method using the phage display described above.
  • the MRLN inhibitor which is the active ingredient of the agent of the present invention, may be a compound that inhibits the function or expression of MRLN.
  • the structure of the compound is not limited as long as it can inhibit the function and expression of MRLN, and may be any of a small molecule compound, a peptide, a sugar, a high molecular compound and the like.
  • the compound can be obtained by screening.
  • ⁇ Evaluation or screening method for MRLN inhibitors As a method for evaluating or screening (selecting) an MRLN inhibitor, any method can be used as long as it can verify the inhibition of intracellular expression or function of MLLN, and specific examples thereof are shown below. In vitro and in vivo verification methods are used.
  • MRLN expression inhibition is used as an index in the evaluation or screening of MRLN inhibitors
  • the inhibitor or a candidate substance thereof is added to cells or tissues expressing MRLN, and the expression level of MRLN mRNA or protein is measured. Examples thereof include a method of comparison with the case where the inhibitor or candidate substance is not added or when the negative control is added.
  • Examples of cells expressing MRLN include myoblasts and myotube cells, and examples of cultured muscle cells include C2C12 cells used in Examples. Cells into which the MRLN gene has been introduced extrinsically may be used.
  • the MRLN inhibitor may be administered to a non-human animal and the expression level of MRLN may be measured in the muscle tissue of the animal, or the MRLN inhibitor may be administered to the isolated muscle tissue and the MRLN may be measured in the muscle tissue. The expression level of may be measured.
  • the method of contacting the MRLN inhibitor with the MRLN-expressing cell is not particularly limited, but when the MRLN inhibitor is a nucleic acid, a method generally used for introducing the nucleic acid into the cell, for example, lipofection. A method, an electroporation method, a nucleic acid method, or the like can be used.
  • the intracellular mRNA expression level of MRLN can be measured by various methods known in the art. Specific examples include Northern blot analysis, competitive polymerase chain reaction (PCR), quantitative real-time PCR, and the like. When the mRNA is isolated, a method well known in the art is used, for example, according to the manufacturer's recommended protocol, SuperPrep Cell Lysis & RT Kit for qPCR (Toyobo), RNeasy Tissue Mini Kit (Qiagen), etc. Can be used. In this way, the expression level of MRLN can be measured.
  • PCR competitive polymerase chain reaction
  • Qiagen RNeasy Tissue Mini Kit
  • the expression level of MRLN in cells can be assayed by various methods known in the art. Specifically, for example, immunoprecipitation, Western blotting (* immunoblotting), enzyme-linked immunosorbent assay (ELISA), quantitative protein assay, protein activity assay (eg, caspase activity assay), immunohistochemistry. Methods, immunohistochemistry methods, fluorescence activated cell sorting (FACS) and the like can be mentioned.
  • MRLN inhibitors when screening or evaluating MRLN inhibitors using the inhibition of MRLN function as an index, for example, calcium uptake into the sarcoplasmic reticulum and calcium release from the sarcoplasmic reticulum may be used as an index. can.
  • an MRLN inhibitor or a candidate substance thereof is present and its effect is affected. By examining, MRLN inhibitors can be screened or evaluated.
  • MRLN inhibitors can also be evaluated or screened using muscle disease model animals.
  • a muscle disease model animal for example, a dystrophin-deficient mouse or a sarcoglycan-deficient mouse can be used.
  • the amount of creatine kinase in blood is increased as compared with normal mice, but the amount of creatine kinase in blood is decreased by administration of an MRLN inhibitor, so that the amount of creatine kinase in blood is decreased.
  • MRLN inhibitors can be evaluated or screened using the amount as an index.
  • the MRLN inhibitor obtained by the selection method of the present invention can be used as a prophylactic and / or therapeutic agent for muscle diseases because it suppresses the onset or progression of muscle diseases. That is, the present invention provides a method for screening a prophylactic and / or therapeutic agent for muscle disease, which comprises a step of selecting an MRLN inhibitor by the above method.
  • the screening method preferably includes a step of evaluating both the ability of the candidate substance to inhibit MRLN expression and the ability of the candidate substance to inhibit MRLN function such as calcium release from the sarcoplasmic reticulum.
  • MRLN inhibitors can treat or prevent muscle diseases.
  • muscle diseases include, but are not limited to, muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disuse muscle atrophy, and sarcopenia. Of these, muscular dystrophy is preferred.
  • Muscular dystrophy typically includes muscular dystrophy having a mutation or deficiency in a component of the dystrophin-glycoprotein complex (DGC), such as Duchenne muscular dystrophy, Becker muscular dystrophy, and limb muscular dystrophy (such as sarcoglycanopathy).
  • DGC dystrophin-glycoprotein complex
  • the sarcoglycanopathies include LGMD2C, LGMD2D, LGMD2E, and LGMD2F.
  • Muscle diseases are preferably diseases associated with abnormal calcium influx in the cytoplasm of muscle cells.
  • the MRLN inhibitor has a function of increasing sarcoplasmic reticulum calcium uptake by inhibiting the function or expression of MRLN, thereby reducing the amount of calcium in the cytoplasm. Therefore, it is effective for the treatment and prevention of the above-mentioned muscle diseases accompanied by abnormal calcium influx into the cytoplasm.
  • DGC deficiency enhances membrane permeability, which increases the amount of calcium in the cytoplasm and causes cell death
  • nNOS neuronitrate synthase
  • MRLN inhibitors suppress the death of muscle cells, maintain and restore muscle contractile force, and treat muscle diseases by reducing the amount of calcium in the cytoplasm and increasing the uptake of calcium in the muscle vesicles. It has an effective and / or preventive effect. That is, the agent of the present invention may be an agent that suppresses muscle cell death or an agent that maintains / restores muscle contractile force.
  • the present invention requires a therapeutic or prophylactic agent for muscle disease containing an MRLN inhibitor as an active ingredient or a pharmaceutical composition for treating or preventing muscle disease; an effective amount of MRLN inhibitor for treating or preventing muscle disease.
  • a method for treating or preventing a muscle disease including a step of administering to a subject; an MRLN inhibitor for treating or preventing the muscle disease; the use of the MRLN inhibitor in the manufacture of a pharmaceutical for treating or preventing the muscle disease. ..
  • the agent of the present invention can be prepared by adding an MRLN inhibitor as it is or by adding a pharmacologically acceptable carrier.
  • a pharmacologically acceptable carrier various conventional organic or inorganic carrier substances are used as the pharmaceutical material, and excipients, lubricants, binders and disintegrants in solid pharmaceuticals; solvents in liquid pharmaceuticals and lysis aids. It is compounded as an agent, a suspending agent, an isotonic agent, a buffering agent, a pain-relieving agent, and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, colorants, and sweeteners can also be used.
  • the agent of the present invention can include a reagent for introducing a nucleic acid.
  • the nucleic acid introduction reagent include liposomes, lipofectin, lipofectamine, DOGS (transferase), DOPE, DOTAP, DDAB, DHDEAB, HDEAB, polybrene, and cationic lipids such as poly (ethyleneimine) (PEI).
  • PES poly (ethyleneimine)
  • the agent of the present invention can be orally or parenterally administered to a subject in need of treatment or prevention of muscle disease.
  • Parenteral administration includes, for example, subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration and the like. Administration may be continuous or long-term, short-term or intermittent.
  • Dosage forms for oral administration include, for example, tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules and microcapsules), syrups, emulsions, and suspensions. Examples include turbidants.
  • examples of the dosage form for parenteral administration include injections, infusions, infusions, suppositories and the like.
  • suitable bases eg, butyric acid polymers, glycolic acid polymers, butyric acid-glycolic acid copolymers, butyric acid polymers and glycolic acid polymers mixtures, polyglycerol fatty acid esters, etc.
  • an excipient such as a binder, a disintegrant, a carrier such as a lubricant, a sweetness, etc.
  • a carrier such as a lubricant, a sweetness, etc.
  • an excipient such as an agent, a surfactant, a suspending agent and an emulsifier.
  • an injection is preferably used as the agent for parenteral administration.
  • injectable preparations include subcutaneous injections, intradermal injections, intramuscular injections, drip injections and the like, in addition to intravenous injections.
  • Such injections are prepared according to methods known per se, for example, by dissolving, suspending or emulsifying an MRLN inhibitor such as the antisense oligonucleotide in a sterile aqueous or oily solution normally used for injections.
  • Aqueous solutions for injection include, for example, phosphate buffered saline, physiological saline, isotonic solutions containing glucose and other adjuvants, and suitable solubilizing agents such as alcohol (eg, ethanol).
  • Polyalcohol eg, propylene glycol, polyethylene glycol
  • nonionic surfactant eg, polysorbate 80, HCO-50 (polyoxyethylene (50mo1) addedut of hydrided castor oil)
  • a buffering agent e.g, a pH adjusting agent, an tonicity agent, a pain-relieving agent, a preservative, a stabilizer and the like
  • Such compositions are produced by known methods.
  • the ratio of the active ingredient, that is, the MRLN inhibitor contained in the agent of the present invention can be appropriately set within a range in which the desired effect can be obtained, but is usually 0.01 to 100% by weight, preferably 0.01 to 100% by weight. Is 0.1 to 99.9% by weight, more preferably 0.5 to 99.5% by weight.
  • the agent of the present invention containing an MRLN inhibitor as an active ingredient is stable, has low toxicity, and can be used safely.
  • the daily dose is not unconditionally defined depending on the type of active ingredient, body weight and age of the subject to be administered, symptoms, etc., but is in the range of 0.1 ng to 1000 mg per 1 kg of body weight, preferably 1 ng at a time. It is possible to select in the range of ⁇ 100 mg / kg / week.
  • the number of administrations of the agent of the present invention is not particularly limited, but is usually about 1 to 10 times per month.
  • the administration period may be short-term administration of several days to one week, long-term administration of several weeks to several months, or several years to several decades. If the symptoms of the disease recur at considerable intervals, the agent of the present invention can be re-administered.
  • the subject of administration of the agent of the present invention is a subject requiring treatment or prevention of muscle disease, but mammals such as mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, cows, horses, sheep, monkeys, and humans. Animals are mentioned, preferably primates, and particularly preferably humans.
  • Example 1 Preparation of Modified Antisense oligonucleotide
  • the modified antisense oligonucleotide was synthesized and purified by Nippon Gene Co., Ltd./Nippon Gene Material Co., Ltd. according to a general solid-phase synthesis method of oligonucleic acid.
  • the compounds were identified by a high-speed liquid chromatographic mass spectrometer.
  • the synthesized MRLN antisense oligonucleotide is a modified antisense oligonucleotide consisting of 16 bases complementary to positions 409 to 424 of the nucleic acid base sequence (SEQ ID NO: 1) of mouse MRLN.
  • Example 2 In vitro MRLN knockdown activity test (Gymnosis method) C2C12 cells were seeded on 384 plates and cultured in a CO 2 incubator. After 3 hours, the MRLN antisense oligonucleotide synthesized in Example 1 was added and cultured in a CO 2 incubator. After about 72 hours, the MRLN antisense oligonucleotide-containing medium was removed from the cells, and Wash was performed with Phosphate-buffered saline (PBS). Then, using SuperPrep Cell Lysis & RT Kit for qPCR (Toyobo), cell lysates containing RNA were prepared, and reverse transcription reaction from lysates was performed to synthesize template cDNA.
  • PBS Phosphate-buffered saline
  • MRLN antisense oligonucleotide As the treatment concentration of the MRLN antisense oligonucleotide, the maximum concentration was 1000 nM, and the one diluted with 4 concentrations having a common ratio of 3 was used, and IC 50 was calculated as the MRLN knockdown activity. The test was carried out three times, and the average value of the IC 50 was calculated to be 119.9 nM. Thus, MRLN antisense oligonucleotides have been shown to inhibit MRLN expression.
  • Example 3 In vivo MRLN Knockdown Activity Test
  • the MRLN antisense oligonucleotide synthesized in Example 1 was prepared with saline to 10 and 50 mg / 5 mL / kg, and was 7-week-old C57BL / 10ScSn-Dmdx / J ( mdx) mice (male, Jackson Laboratory) were administered intravenously to the tail vein.
  • the mdx mouse is the most used mouse as a model mouse for DMD.
  • All blood was collected from the abdominal vena cava under isoflurane (Pfizer) anesthesia and killed. After lethality, the tibialis anterior muscle was collected and RNAlater Soln.
  • MRLN antisense oligonucleotide was shown as the amount ratio of MRLN to 18S rRNA as a relative value to the vehicle group. The results are shown in FIG. MRLN antisense oligonucleotides have been shown to inhibit MRLN expression in muscle.
  • Example 4 MRLN antisense oligonucleotide administration test for muscular dystrophy model mice
  • the MRLN antisense oligonucleotides synthesized in Example 1 were prepared in physiological saline at appropriate concentrations, and were prepared in mdx mice, sarcoglycan ⁇ (Sgcb) knockout mice, and It is administered intravenously to the sarcoglycan ⁇ (Sgca) knockout mouse, sarcoglycan ⁇ (Sgcg) knockout mouse, sarcoglycan ⁇ (Sgcd) knockout mouse, or dystrophin / utophin double knockout mouse.
  • RNA extraction for gene analysis is performed according to the protocol described in the kit after adding RLT buffer of RNeasy Fiberous Tissue Mini Kit (Qiagen) to the tissue and disrupting it using a multi-bead shocker.
  • MRLN antisense oligonucleotides synthesized in Example 1 were prepared with saline to a concentration of 3 and 10 mg / 5 mL / kg and were 8 week old C57BL / 10ScSn-Dmdmdx / J (mdx) mice (male, Jackson). Laboratory) was administered intravenously to the tail vein. It was administered once or twice a week, and one week after the final administration, all blood was collected from the abdominal vena cava under the anesthesia of isoflurane (Pfizer Japan Inc.) and killed.
  • the MRLN antisense oligonucleotide was prepared in physiological saline so as to be 10 and 50 mg / 5 mL / kg, and was intravenously administered to 15-week-old sarcoglycan ⁇ (Sgcb) knockout mice.
  • the Sgcb knockout mouse is a model mouse of sarcoglycanopathy and was created by deleting Exon2 of the Sgcb gene.
  • Three days after administration all blood was collected from the abdominal vena cava under anesthesia of sevoflurane (Maruishi Pharmaceutical Co., Ltd.) and the patient was killed. After lethality, the tibialis anterior muscle was collected and RNAlater Soln. It was immersed in (invitrogen).
  • Example 5 Intracellular calcium measurement test using cells derived from muscular dystrophy patients DMD and myoblasts derived from sarcoglycanopathies (LGMD2E) patients are seeded on 96 well plates or 384 well plates and cultured in a CO 2 incubator. During the culture period, cells are induced to differentiate in a semi-confluent state. After the cells have differentiated into myotubes, they are treated with MRLN antisense oligonucleotides or siRNA mixed with MRLN antisense oligonucleotides or siRNAs or transfection reagents (such as Lipofectamine RNAi Reagent) and further cultured in a CO 2 incubator.
  • MRLN antisense oligonucleotides or siRNA mixed with MRLN antisense oligonucleotides or siRNAs or transfection reagents such as Lipofectamine RNAi Reagent
  • the MRLN antisense oligonucleotide or siRNA used is an antisense oligonucleotide or siRNA that is complementary to a part of the nucleic acid base sequence (SEQ ID NO: 3) of human MRLN.
  • SEQ ID NO: 3 the nucleic acid base sequence of human MRLN.
  • a few days after treatment with the MRLN antisense oligonucleotide or siRNA, the MRLN antisense oligonucleotide or siRNA-containing medium is removed from the cells, a loading die containing calcium Dye is added, and the cells are cultured at room temperature. After 1 hour, intracellular calcium measurement by FDSS is performed. A ryanodine receptor agonist or the like is used to stimulate cells during calcium measurement. Confirm an increase in intramuscular calcium in patient-derived cells by MRLN antisense oligonucleotide or siRNA treatment.
  • the intracellular calcium measurement was performed as follows. DMD patient-derived cells (NCNP Muscle Repository) were seeded on a 384-well plate, cultured, and then induced to differentiate into myotube cells. After differentiation into myotubes, RNAi Silencer Select siRNA (Thermo Fisher) as a siRNA against the nucleic acid base sequence (SEQ ID NO: 3) of Lipofectamine RNAiMAX Transfection Reagent (invitrogen) and human MRLN, or Silencer as a negative control. 1 siRNA (Thermo Fisher) was mixed, then added to the cells, and further cultured in a CO 2 incubator.
  • a loading die containing Cal-520 (AAT Bioquest) was added, and after culturing at room temperature for 1 hour, an excitation wavelength of 480 nm and a detection wavelength of 540 nm were used using FDSS7000EX (Hamamatsu Photonics).
  • the fluorescence value was measured at 1-second intervals for 10 minutes. The fluorescence value was measured for 1 minute and used as the baseline.
  • ryanodine receptor agonist 4-Chloromethcyne (CMC: Kanto Chemical Co., Inc.) was added to a final concentration of 1 mM, and the measurement was continued for another 9 minutes.
  • the value obtained by subtracting the baseline from the maximum value of the increase in fluorescence value due to the increase in intracellular calcium concentration was calculated, and the value was analyzed as the amount of calcium in the muscle vesicle.
  • the results are shown in FIG. Since the amount of calcium released from the muscle vesicles was increased by the siRNA treatment, it was shown that the amount of calcium in the muscle vesicles was increased by the MRLN knockdown by siRNA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2021/026798 2020-07-17 2021-07-16 筋疾患の予防または治療剤 Ceased WO2022014703A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022536461A JPWO2022014703A1 (https=) 2020-07-17 2021-07-16
US18/005,520 US20230272386A1 (en) 2020-07-17 2021-07-16 Agent for preventing or treating muscular disease
EP21842938.9A EP4183416A4 (en) 2020-07-17 2021-07-16 AGENT FOR PREVENTING OR TREATING MUSCULAR DISEASE
CN202180061076.3A CN116209478A (zh) 2020-07-17 2021-07-16 肌病的预防或治疗剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020-122975 2020-07-17
JP2020122975 2020-07-17
JP2021-025158 2021-02-19
JP2021025158 2021-02-19

Publications (1)

Publication Number Publication Date
WO2022014703A1 true WO2022014703A1 (ja) 2022-01-20

Family

ID=79555651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/026798 Ceased WO2022014703A1 (ja) 2020-07-17 2021-07-16 筋疾患の予防または治療剤

Country Status (5)

Country Link
US (1) US20230272386A1 (https=)
EP (1) EP4183416A4 (https=)
JP (1) JPWO2022014703A1 (https=)
CN (1) CN116209478A (https=)
WO (1) WO2022014703A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206092A1 (ja) * 2024-03-27 2025-10-02 田辺三菱製薬株式会社 Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62296890A (ja) 1986-03-27 1987-12-24 メディカル　リサーチ　カウンスル 組換えｄｎａ生産物及び製造法
JPH0373280B2 (https=) 1984-08-15 1991-11-21 Shingijutsu Kaihatsu Jigyodan
JPH04504365A (ja) 1990-01-12 1992-08-06 アブジェニックス　インコーポレイテッド 異種抗体の生成
JPH04506458A (ja) 1989-12-21 1992-11-12 セルテック　リミテッド Ｃｄ３特異的組換え抗体
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US20040171570A1 (en) 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US20160228502A1 (en) * 2015-02-05 2016-08-11 University Of Maryland, Baltimore Regulating calcium in excitable cells with a novel protein
US20170298107A1 (en) * 2016-04-19 2017-10-19 The Board Of Regents Of The University Of Texas System Use of a small native peptide activator of serca pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
JP2017214337A (ja) * 2016-06-01 2017-12-07 国立研究開発法人国立精神・神経医療研究センター 筋ジストロフィー治療剤
WO2020100826A1 (ja) 2018-11-12 2020-05-22 田辺三菱製薬株式会社 架橋型人工核酸ａｌｎａ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0373280B2 (https=) 1984-08-15 1991-11-21 Shingijutsu Kaihatsu Jigyodan
JPS62296890A (ja) 1986-03-27 1987-12-24 メディカル　リサーチ　カウンスル 組換えｄｎａ生産物及び製造法
JPH04506458A (ja) 1989-12-21 1992-11-12 セルテック　リミテッド Ｃｄ３特異的組換え抗体
JPH04504365A (ja) 1990-01-12 1992-08-06 アブジェニックス　インコーポレイテッド 異種抗体の生成
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US20040171570A1 (en) 2002-11-05 2004-09-02 Charles Allerson Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US20160228502A1 (en) * 2015-02-05 2016-08-11 University Of Maryland, Baltimore Regulating calcium in excitable cells with a novel protein
US20170298107A1 (en) * 2016-04-19 2017-10-19 The Board Of Regents Of The University Of Texas System Use of a small native peptide activator of serca pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
JP2017214337A (ja) * 2016-06-01 2017-12-07 国立研究開発法人国立精神・神経医療研究センター 筋ジストロフィー治療剤
WO2020100826A1 (ja) 2018-11-12 2020-05-22 田辺三菱製薬株式会社 架橋型人工核酸ａｌｎａ

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Antibody Engineering - a Practical Approach", 1996, IRL PRESS
"Phage display a laboratory manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
AM J PHYSIOL CELL PHYSIOL., vol. 308, no. 9, pages C699 - 709
ANDERSON, DOUGLAS M. ET AL.: "A Micropeptide Encoded by a Putative Long Noncoding RNA Regulates Muscle Performance", CELL, vol. 160, 2015, pages 595 - 606, XP029139829, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.cell2015.01.009> DOI: 10.1016/j.cell.2015.01.009 *
CHATTOPADHYAYA ET AL., J. ORG. CHEM., vol. 74, 2009, pages 118 - 134
EXP.OPIN.THER.PATENTS, vol. 6, no. 5, 1996, pages 441 - 456
EXPERIMENTAL MEDICINE (EXTRA ISSUE, vol. 6, no. 10, 1988
KOEHLERMILSTEIN ET AL., NATURE, vol. 256, 1975, pages 495 - 497
NATURE GENETICS, vol. 15, 1997, pages 146 - 156
NATURE GENETICS, vol. 7, 1994, pages 13 - 21
NATURE, vol. 348, 1990, pages 552 - 554
NATURE, vol. 368, 1994, pages 856 - 859
See also references of EP4183416A4
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 - 489
ZHANGMADDEN, GENOME RES, vol. 7, 1997, pages 649 - 656

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206092A1 (ja) * 2024-03-27 2025-10-02 田辺三菱製薬株式会社 Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物

Also Published As

Publication number Publication date
US20230272386A1 (en) 2023-08-31
EP4183416A4 (en) 2025-08-27
EP4183416A1 (en) 2023-05-24
JPWO2022014703A1 (https=) 2022-01-20
CN116209478A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
KR102941589B1 (ko) 프리온 발현을 감소시키기 위한 화합물 및 방법
US20180155414A1 (en) Targeting Apolipoprotein E (APOE) in Neurologic Disease
AU2016201644B2 (en) Detection and treatment of fibrosis
US8877188B2 (en) Detection and treatment of non-dermal fibrosis
JP2022536085A (ja) 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法
WO2011112732A2 (en) Methods of treating vascular inflammatory disorders
WO2014093773A1 (en) Methods and assays relating to macrophage differentiation
EP2875049B1 (en) Methods for preventing and treating chronic kidney disease (ckd)
WO2022014703A1 (ja) 筋疾患の予防または治療剤
EP2575883B1 (en) Treatment of inflammatory disorders
EP2303325A2 (en) Inhibition of emmprin to treat multiple sclerosis
EP4709857A1 (en) Methods of treatment of chronic kidney disease
JP2025077049A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
JP2007537167A (ja) ホスホリパーゼｃガンマの調節、並びにそれによる疼痛及び侵害受容の制御
WO2009026705A1 (en) Method of diagnosing and treating osteoarthritis
HK1183322B (en) Cadherin-11 antagonist for the treatment of fibrosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21842938

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022536461

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021842938

Country of ref document: EP

Effective date: 20230217